early-stage disease. 3 Therefore, new early diagnostic biomarkers are urgently needed for NSCLC.
Non-small-cell lung cancer is characterized by a diverse collection of genomic alterations, and many pathogenetically important changes have already been identified in a substantial proportion of patients and classified as disease biomarkers. 4 Interpretation of the molecular profiles of NSCLC is crucial for early detection and effective personalized treatment approaches. At present, multiple blood-based biomolecules and biosources for cancer have been the subject of research, including cell-free (cf) DNA, cfRNA, proteins, metabolic products, extracellular vesicles, and circulating tumor cells (CTCs); blood platelets have also joined this array of blood-based biosources. 5 Platelets have important functions in hemostasis, immunity, and inflammation and also play a key role in cancer growth and metastasis. 6 The functions of tumor-educated platelets (TEPs) have changed significantly, indicating the alterations in platelets RNA profile. 7 The combination of specific splice events in response to external signals and the capacity of platelets to sequester tumorassociated biomolecules can provide TEPs with a highly dynamic mRNA repertoire, with potential applicability to cancer diagnosis. 8, 9 In addition, miRNAs also play an important role in altering TEP RNA profile as post-transcriptional regulators.
We believe that blood platelets could provide an eligible biomaterial source for RNA biomarkers of NSCLC diagnosis. The high-throughput platforms for analysis of gene expression such as next-generation sequencing (NGS) are increasingly valued and common in medical oncology with great clinical applications, allowing testing of multiple genetic variants from a single sample, 10 which have led to the identification of genetic variation and molecular biomarkers serving for personalized medicine. 11 The research group of Best et al demonstrated that TEPs with altered RNA profiles which were able to distinguish 55 healthy individuals from 228 cancer patients with 96% accuracy using RNA-seq, and also developed a particle-swarm optimization (PSO)-driven thromboSeq algorithm which resulted in TEP-based detection of early-stage NSCLC with accuracy 81%.
In this study, we downloaded the NGS datasets from several studies which had identified panels of differential mRNAs for cancer
diagnosis, and aimed to analyze these datasets in deep and explore the causes of changes in TEP RNA profile utilizing integrated bioinformatics analysis, and finally to conclude the biological functions and key pathways of these common differential mRNAs, thereby
proposing an insight in molecular regulatory mechanisms and potential candidate biomarkers for early diagnosis and individualized therapy of NSCLC.
| MATERIAL S AND ME THODS

| NGS datasets and differentially expressed mRNAs/miRNAs between NSCLC patients and health donors
The platelet mRNA expression profile of GSE68086 and GSE89843
from Gene Expression Omnibus (GEO) DataSets (https://www.ncbi.
nlm.nih.gov/gds/) was obtained, both of which were collected from high-throughput sequencing, based on GPL16791 platform (Illumina Hiseq 2500). Exosomal miRNAs data were obtained from previous research which was implemented by miRNA-seq using Illumina We identified 951 commonly altered differential mRNAs from above platelets RNA-sequencing datasets, among them only 2 were consistently up-regulated and 18 were consistently down-regulated ( Figure 1 and Table 1 ).
| GO enrichment and KEGG pathway analysis of differentially expressed mRNAs in platelets between NSCLC patients and health donors
Above 20 consistently altered mRNAs were mapped and subjected to relevant biological annotation analysis in the DAVID database.
GO analysis results showed that differentially expressed mRNAs were significantly enriched in several biological processes, including transport, establishment of localization, localization, single-organism transport and single-organism localization. For cell component, the 20 consistently altered mRNAs were significantly enriched in cytoplasm, intracellular membrane-bounded organelle, cytoplasmic part, endomembrane system and membrane-bounded vesicle. In addition, molecular function displayed that they were enriched in catalytic activity ( Table 2 ). The most significantly enriched pathways of the 20 consistently altered mRNAs analyzed by KEGG analysis. They were enriched in complement and coagulation cascades but showed no significant difference, and the main differentially expressed mRNAs involved in the functions and pathways were down-regulated (Table 2) . derived exosomal miRNA were identified by miRNA-seq using an Illumina HiSeq4000 analyzer. 12 The total differentially expressed miRNAs were composed of 98 up-regulated miRNAs and 108 downregulated miRNAs.
Next, we predicted miRNA which regulated above 20 consistently altered mRNA using miRNA targets prediction tools as described in Materials and methods. Sixty-nine miRNAs that reg- Subsequently, miRNA-mRNA network about consistently upregulated exosomal miRNAs and consistently down-regulated mRNAs in platelets was constructed ( Figure 3 ).
We found miRNAs that regulated consistently altered mRNAs did not exactly matched the differentially expressed miRNAs in exosomes, suggesting miRNAs influenced mRNA level by other mechanisms in addition to the direct regulation. We hypothesized that miRNA might influence the expression of mRNAs through regulating the levels of distinct spliceosomal proteins. 
| Spliceosomal mRNAs and their miRNA predictions
Platelets were able to escape the nuclear confines and to splice premRNA by a functional spliceosome which could alter their pool of translatable messages in response to external stimulation. 18 We selected 13 distinct spliceosomal proteins (Table 3) according to previous study 18 and predicted 338 miRNAs that regulated their mRNAs. 
| D ISCUSS I ON
Lung cancer is a severe disease, and its morbidity and mortality are gradually increasing. 19 This study identified 951 commonly altered mRNAs in TEPs compared with control samples; however, only 20 consistently altered mRNAs were selected between two mRNA-seq datasets probably due to the post-transcriptional regulation and alternative splicing events during genes expression, indicating the great variation of platelet mRNAs. Then, these differentially expressed mRNAs were subjected to GO and KEGG pathway analysis using bioinformatics approaches, demonstrating they were involved in the biological process of transport and localization and the molecular function of catalytic activity. F13A1 and F2R were included in KEGG pathway of complement and coagulation cascades. F2R is a G protein-coupled receptor which could regulate coagulation and cell survival, and the serum levels of F2R might act as the diagnostic marker in lung cancer. 23 A unique case reported a highly aggressive angiosarcoma complicated with inherited factor XIII deficiency which was encoded by F13A1.
24
Many researchers have reported that miRNAs are important post-transcriptional regulators in all biological processes virtually. 25 MiRNAs are short, single-strand, noncoding RNAs of approximately 20-25 nucleotides which bind to complementary sequences mainly located at the 3′-untranslated region (3′-UTR) of their target mRNAs for degradation or the induction of translational repression. 17 It has been established that tumor cells can release RNA into the circulation via a variety of microvesicles, which could help tumor-derived RNA transfer into platelets, although microvesicleindependent mechanisms were also involved in this process. 9 In NSCLC, tumor-derived exosomal miRNAs expression profiles had been identified with remarkably high predictive values including 206 most significant AC-and SCC-specific miRNAs. 12 Twenty consistently altered mRNAs in platelets could be regulated by total 229 26 From the data and network, we knew that 7 miRNAs exerted their functional effects by targeting multiple mRNAs usually in the same pathway, 27 suggesting blood platelets not only took up tumor-derived microvesicle that contained tumor-associated mRNA but also altered the mRNA profiles by the regulation of miRNAs from exosomes.
Anucleate as platelets are, they contain mRNA, the entire spliceosome machinery as well as a full complement of ribosomes, and have the ability to synthesize de novo proteins upon activation. 28 Megakaryocytes can produce large quantities of mRNA and protein which are packaged into platelets prior to their release in to the circulation. 29 The TEPs perhaps behave in a "semi-activational state," which are able to splice pre-mRNA with the help of functional spliceosome and several splice factor proteins. 30 Moreover, there are very many exon skip splice isoforms in human platelets which are characterized by the peptides spanning the exon-exon junction of a novel splicing event. 31 Calverly et al 8 identified a subset of megakaryocyte/plateletderived mRNAs that were differentially expressed in lung cancer metastasis. Alternative Splicing and Exon Skipping in TEPs of patients with NSCLC caused specific changes in platelet RNAs.
We took the 13 mRNAs that encoded spliceosomal proteins, 9
of them were referred in GSE68086 and 6 of them were contained in GSE89843. We found that 17 miRNAs which regulated SRSF1, SNRPD1, SRRM1, SRSF3, SRSF7, SRSF2, and SRSF5 were up- 
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